Nurix Therapeutics, Inc. revenue by segment NRIX

Nurix Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Aug 31, 2026 was License Revenue at $653.2 million, 97% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Aug 31, 2026
Q3 FY2026
Aug 31, 2026
Q2 FY2026
May 31, 2026
Q1 FY2026
Feb 28, 2026
Q4 FY2025
Nov 30, 2025
Q3 FY2025
Aug 31, 2025
Q2 FY2025
May 31, 2025
Q1 FY2025
Feb 28, 2025
Q4 FY2024
Nov 30, 2024
Revenue
702
673
9
6
14
8
44
18
13
License Revenue
653
share 93.1%
653
share 97.0%
—
—
0
share 0.0%
—
30
share 68.1%
—
—
Collaboration Revenue
49
-9.1%
share 6.9%
20
+152.2%
share 3.0%
9
-35.7%
share 100.0%
6
-66.1%
share 100.0%
14
+2.2%
share 100.0%
8
share 100.0%
14
share 31.9%
18
share 100.0%
13
share 100.0%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRIX (Nasdaq)
Fiscal year ends
November 30
Incorporated in
DE
Headquarters
Brisbane, CA
SEC filer status
Large accelerated filer
SEC CIK
1549595
Former names
Nurix, Inc. (until Sep 18, 2015)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.